GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 61-72 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Glucagon-like Peptide-1 Receptor Agonists Are Not Associated with Increased Risk of Acute Pancreatitis or Pancreatic Complications, Including Pancreatic Cancer, in Type 2 Diabetes: A Global Propensity-Matched Cohort Study.

Sun Y; Liu B; Loh H; Mathialagan S; Lin CH; Tarabichi Y; Veccia D; Wong R; Tse W; Song G

Jan 1, 2026Journal of personalized medicine

2026PubMedDirectly related

Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study.

Kazi MAI; Mufarrih SM; Sirohi A; Hasan F; Sharma A; Singh S; Muganlinskaya N; Haq N

Jan 1, 2026PloS one

2026PubMedDirectly related

Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes.

Khadija HA; Alnees M; Abdullah A; Ibraheem K; Makhlouf TZ; Cohen R; Najajra D; Twito O; Schiller T; Kirzhner A

Jan 1, 2026Diabetes & metabolism

2026PubMedDirectly related

Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production.

Hansell L; Zhu W; Lynch M; Hocking SL; Celermajer DS; Sack F

Jan 1, 2026BMJ open

2026PubMedDirectly related

AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review.

Arab JP; Malhi H; Winder GS; Fontana RJ

Jan 1, 2026Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

2026PubMedDirectly related

Semaglutide in postmenopausal women: Clinical implications for weight loss, muscle health, and sleep-disordered breathing.

Pereira NRM; Ishikura IA; Tufik S; Hachul H

Jan 1, 2026Maturitas

2026PubMedDirectly related

Systematic review of cost-effectiveness analyses of weight loss interventions for knee osteoarthritis.

Gao Y; Mistry H; Dhaif F; Mcmurray B; Susarla S; Naghdi S

Jan 1, 2026BMJ open

2026PubMedDirectly related

Patient characteristics and early experiences with anti-obesity medications: the CAMP study.

Tewksbury C; Soliva EA; Scheffey K; Kwong PL; Glanz K

Jan 1, 2026Frontiers in nutrition

2026PubMedDirectly related

[New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise].

Barton A; Schattenberg JM

Jan 1, 2026Zeitschrift fur Gastroenterologie

2026PubMedDirectly related

Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.

Kassem S

Jan 1, 2026Diabetes, obesity & metabolism

2026PubMedDirectly related

Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study.

Carafa A; Sessa RL; Amendolara R; Zampetti S; Mignogna C; Sciarra F; D'Onofrio L; Risi R; Venneri MA; Cavallari I; Maddaloni E; Buzzetti R

Jan 1, 2026Acta diabetologica

2026PubMedDirectly related

Euglycaemic ketoacidosis associated with dual-acting GLP-1/GIP receptor agonist treatment following bariatric surgery.

Green D; Glynn N

Jan 1, 2026Endocrinology, diabetes & metabolism case reports